Abstract
The R-CHOP regimen has been found to improve the outcome of diffuse large B-cell lymphoma (DLBCL). However, it does not provide a satisfactory treatment outcome in the high-risk group. We previously administered the CyclOBEAP regimen to patients with DLBCL, and reported its safety and efficacy. The R-CyclOBEAP regimen was administered over a total period of 12 weeks, and rituximab 375 mg/m(2) was given every 2 weeks. There were 101 eligible patients. CR was achieved in 96 patients (95%). The 5-year overall survival (OS) rate was 85% and progression-free survival (PFS) rate was 76%. When the patients were divided according to the IPI, the 5-year OS and PFS rates did not significantly differ among the risk groups. The 5-year PFS of the germinal centre B-cell group was 80% and that of the non-GCB group was 74% (NS). Univariate analysis showed that the presence of B symptoms, extranodal lesions >or=2, and sIL-2R were significant poor prognostic factors. Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients. The addition of rituximab to CyclOBEAP therapy may enhance the effect of CyclOBEAP therapy for DLBCL.
(c) 2010 John Wiley & Sons, Ltd.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Drug Administration Schedule
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Humans
-
Kaplan-Meier Estimate
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Prednisolone / administration & dosage
-
Prednisolone / adverse effects
-
Prognosis
-
Rituximab
-
Thrombocytopenia / chemically induced
-
Treatment Outcome
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
-
Young Adult
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Bleomycin
-
Rituximab
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone